Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
26 Feb 2021
26 Feb 2021
Historique:
received:
29
01
2021
accepted:
29
01
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
Shugan Jieyu capsule can reduce blood pressure and improve its concomitant symptoms. However, it is not widely used in clinic because of its incomplete understanding of its nature. There are many reports on the clinical trials of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression in recent years. However, the lack of systematic review and meta-analysis has not provided effective evidence. As a consequence, we provide a protocol to evaluate the efficacy and safety of Shugan Jieyu capsule (SJC) in the treatment of essential hypertension (EH) with insomnia, anxiety or depression. The search time range of Cochrane Library, PubMed, excerpt Database (EMBASE), Chinese Biomedical Literature Database (CBM), China National knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP), and Wanfang Database (WanFang), was searched by computer from the establishment of the database to December 31, 2020. In the meanwhile, the list of references and related reviews were checked. The data were extracted by 2 evaluators independently, and the literature quality was evaluated according to Cochrane manual 4.2.2. In addition, CochraneRevman5.3 software was used for heterogeneity test, meta-analysis, publication bias analysis and GRADE3.6 evidence quality classification system evaluation related statistical data. This study intends to evaluate the efficacy and safety of SJC in the treatment of EH from many aspects, including changes in blood pressure [systolic blood pressure (SBP), diastolic blood pressure (DBP)], effective rate of blood pressure reduction, improvement rate of concomitant symptoms and adverse reactions. The conclusion of systematic review intends to provide evidence for judging that SJC is an effective intervention for EH patients with insomnia, anxiety and depression. PROSPERO CRD 42021219704.
Sections du résumé
BACKGROUND
BACKGROUND
Shugan Jieyu capsule can reduce blood pressure and improve its concomitant symptoms. However, it is not widely used in clinic because of its incomplete understanding of its nature. There are many reports on the clinical trials of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression in recent years. However, the lack of systematic review and meta-analysis has not provided effective evidence. As a consequence, we provide a protocol to evaluate the efficacy and safety of Shugan Jieyu capsule (SJC) in the treatment of essential hypertension (EH) with insomnia, anxiety or depression.
METHODS
METHODS
The search time range of Cochrane Library, PubMed, excerpt Database (EMBASE), Chinese Biomedical Literature Database (CBM), China National knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP), and Wanfang Database (WanFang), was searched by computer from the establishment of the database to December 31, 2020. In the meanwhile, the list of references and related reviews were checked. The data were extracted by 2 evaluators independently, and the literature quality was evaluated according to Cochrane manual 4.2.2. In addition, CochraneRevman5.3 software was used for heterogeneity test, meta-analysis, publication bias analysis and GRADE3.6 evidence quality classification system evaluation related statistical data.
RESULTS
RESULTS
This study intends to evaluate the efficacy and safety of SJC in the treatment of EH from many aspects, including changes in blood pressure [systolic blood pressure (SBP), diastolic blood pressure (DBP)], effective rate of blood pressure reduction, improvement rate of concomitant symptoms and adverse reactions.
CONCLUSION
CONCLUSIONS
The conclusion of systematic review intends to provide evidence for judging that SJC is an effective intervention for EH patients with insomnia, anxiety and depression.
PROSPERO REGISTRATION NUMBER
UNASSIGNED
PROSPERO CRD 42021219704.
Identifiants
pubmed: 33663107
doi: 10.1097/MD.0000000000024856
pii: 00005792-202102260-00070
pmc: PMC7909162
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24856Subventions
Organisme : State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
ID : No. XSLP-2013-35
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to disclose.
Références
Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population based screening study (China PEACE Million Persons Project). Lancet 2017;10112:2549.
Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008;25:2679.
Yin GQ, Zhou XH. Current situation of hypertension epidemiology research. Electronic J Clin Med Literature 2018;5:189–90.
Hu SS, Gao RL, Liu LS, et al. Summary of China Cardiovascular Disease Report 2018. Chin J Circul 2019;34:209–20.
Wang ZW, Yang Y, Wang W, et al. New features of the epidemic of hypertension in my country——highlights and enlightenment of China's hypertension survey. Chin J Circulation 2018;33:937–9.
Moulton CD, Costafreda SG, Horton P, et al. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. Brain Imaging Behavior 2015;9:651–62.
Bădescu SV, Tătaru C, Kobylinska L, et al. The association between diabetes mellitus and depression. J Med Life 2016;9:120–5.
Shaaban CE, Jia Y, Chang CCH, et al. Independent and joint effects of vascular and cardiometabolic risk factor pairs for risk of all-cause dementia:a prospective population-based study. Int Psychogeriatr 2019;31:1–2.
Pectol DC, Khan S, Chupik RB, et al. Toward the optimization of dinitrosyl iron complexes as therapeutics for smooth muscle cells. Mol Pharmaceut 2019;16:3178–87.
Song J, Li YF, Zhu XY, et al. The effect of cognitive behavioral therapy combined with Shugan Jieyu capsule on patients with insomnia and the influence of negative emotion and cognitive function. Int J Psychiatry 2020;47:510–3.
Gordon H. Guyatt, Andrew D. Oxman, Gunn E. Vist, et al. GRADE Working Group. GRADE: Grade of Evidence Quality and Strength of Recommendation Consensus. Chin J Evidence Based Med 2009;9:8–11.
Gao ZY, Huang M, Yang KJ. Thinking and analysis of the clinical positioning of traditional Chinese medicine in the treatment of hypertension. World Chin Med 2017;11:541–5.
Shanghai Science and Technology Press, Nanjing University of Traditional Chinese Medicine. Dictionary of Traditional Chinese Medicine [M]. 2006;3093-3095.
Zhao RH, Zhang JP. 30 cases of depression treated by integrated traditional Chinese and Western Medicine. Chinese Folk Therapy 2011;19:54–5.